SECTORS TODAY
Tech XLK -4.89%
Financials XLF -0.76%
Healthcare XLV +0.45%
Energy XLE +1.91%
Industrials XLI -1.60%
Cons. Disc. XLY -0.71%
Cons. Staples XLP +1.41%
Utilities XLU +0.67%
Materials XLB +0.40%
Real Estate XLRE +0.26%
Comm. Svcs XLC -1.29%

Earnings release · CBOE

Cboe Global Markets Reports Results for Third Quarter 2026

Cboe Global Markets, Inc. · Filed · SEC Form 8-K, Item 2.02

Cboe Global Markets, Inc. company page Original on SEC.gov ↗

Revenue $712.2 million +18% vs a year ago
EPS $4.08 +43% vs a year ago
Guidance loweredoutlook statement
Automated extract. The items below were picked out of the company's press release by software and may be wrong or incomplete. Please read the original before relying on any figure. Not investment advice.

Why it matters

Revenue climbed 18% year on year to $712.2 million, and EPS rose 43% to $4.08. Sales and earnings both ahead of a year ago is generally the cleaner kind of result. The company cut its guidance, which is usually read as management's view of coming periods weakening.

Written automatically by Stocknote's note engine from the figures on this page and the company's previous release. Every number in this note is checked against those figures. Not investment advice.

What the company states

Revenue

$712.2 million +18% vs a year ago

…Net Revenue for the Quarter of $712.2 million, Up 18 percent…
EPS

$4.08 +43% vs a year ago

…Record Diluted EPS for the Quarter of $4.08, Up 43 percent…
Guidance

Guidance lowered

…a Vantage organic net revenue growth target2 to ‘mid teens’ from ‘low teens’, and lowering adjusted operating expense guidance to $830 to $845 million from $838 to $853 million.” *All comparisons are third quarter…

Read the original press release on SEC.gov ↗ Filing index ↗

Trend: last 1 reports

All releases →

Revenue growth (YoY)

EPS growth (YoY)

Disclaimer: This page is generated automatically from public SEC filings for information only. Stocknote does not edit the company's release and does not guarantee the accuracy of the extracted items. Read the full disclaimer here.

Get new research in your inbox

Forensic equity research on US stocks. No spam, unsubscribe anytime.